跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 70 条关于
“CaV1.3”
全部
70
临床试验
20
药物
37
机构
0
资讯
13
7个月前
Lario Therapeutics Secures $2.4M to Advance Neuronal Calcium Channel Platform for Parkinson's and PTSD
去年
Channel Therapeutics' NaV1.7 Inhibitor Shows Promising Results for Ocular Pain in Preclinical Trials
去年
UHKT Launches Phase I Trial of Linea DNA-Enabled CAR T-Cell Therapy for AML
去年
Metrion Biosciences Unveils Breakthrough NaV1.9 Screening Assay to Accelerate Non-Opioid Pain Therapeutics Development
去年
FDA Clears HuidaGene's CRISPR-Cas13 RNA-Editing Trial for Macular Degeneration
去年
HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 Cleared for US Trial in Macular Degeneration
2年前
Novel NaV1.8 Inhibitors Lead Wave of Non-Opioid Pain Treatments as Industry Tackles Opioid Crisis
去年
FDA Clears HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 for nAMD
去年
Quiver Bioscience Names Co-Founder Graham Dempsey CEO to Advance Nav1.7-Targeting ASO for Chronic Pain
3个月前
Suzetrigine: A Novel NaV1.8 Blocker for Acute Pain Shows Promise but Falls Short of Opioid Superiority
第 1 页,共 2 页
上一页
下一页